Skip to main content
. 2023 Jul 3;7:64. doi: 10.1038/s41698-023-00409-5

Fig. 3. Vulnerability of PBRM1 deficient biliary tract cancer to DNA damage repair targeting agents.

Fig. 3

a Immunoblot showing the duration of a siRNA-mediated knockdown of PBRM1 in the EGI-cell line. GAPDH was used as a loading control. A representative of three biological replicates is shown. b Relative mRNA expression (mean ± SD of at least three independent experiments) of PBRM1 over 168 h after the siRNA-mediated knockdown. c Four parameter least-squares non-linear regression models of dose-response relation comparing treatment with niraparib, olaparib, berzosertib, or niraparib + berzosertib in PBRM1-deficient cells to PBRM1-proficient cells. Comparison of LogIC50 values of three independent experiments. Points and error bars represent mean ± SD. d Abdominal CT-scan of a patient with a PBRM1-mut BTC treated with niraparib over an 8-week time course (left: before treatment, middle: 4 weeks after treatment start, right: 8 weeks after treatment start).